484 related articles for article (PubMed ID: 20231398)
21. Bactericidal activities of povidone-iodine against Mycobacterium.
Rikimaru T; Kondo M; Kondo S; Oizumi K
Dermatology; 1997; 195 Suppl 2():104-6. PubMed ID: 9403266
[TBL] [Abstract][Full Text] [Related]
22. In vitro antibiotic susceptibility of rapidly growing nontuberculous mycobacteria isolated from patients with microbial keratitis.
Reddy AK; Garg P; Babu KH; Gopinathan U; Sharma S
Curr Eye Res; 2010 Mar; 35(3):225-9. PubMed ID: 20373881
[TBL] [Abstract][Full Text] [Related]
23. [Antimycobacterial activities of a new quinolone, sparfloxacin].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089
[TBL] [Abstract][Full Text] [Related]
24. Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis.
Ashtekar DR; Costa-Periera R; Shrinivasan T; Iyyer R; Vishvanathan N; Rittel W
Diagn Microbiol Infect Dis; 1991; 14(6):465-71. PubMed ID: 1802533
[TBL] [Abstract][Full Text] [Related]
25. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST.
Hombach M; Somoskövi A; Hömke R; Ritter C; Böttger EC
Int J Med Microbiol; 2013 Jul; 303(5):270-6. PubMed ID: 23689069
[TBL] [Abstract][Full Text] [Related]
26. Highly active antimycobacterial derivatives of benzoxazine.
Petrlíková E; Waisser K; Divišová H; Husáková P; Vrabcová P; Kuneš J; Kolář K; Stolaříková J
Bioorg Med Chem; 2010 Dec; 18(23):8178-87. PubMed ID: 21044844
[TBL] [Abstract][Full Text] [Related]
27. [Clinical analysis of 96 cases with pulmonary disease caused by nontuberculous mycobacteria].
Xia X; Gui X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Apr; 22(4):239-41. PubMed ID: 11775923
[TBL] [Abstract][Full Text] [Related]
28. Preliminary study of the in vitro activity of irloxacin against mycobacteria.
Casal M; Gutierrez J; Ruiz P; Moreno G
Chemotherapy; 1995; 41(3):204-7. PubMed ID: 7656667
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria.
Texier-Maugein J; Mormède M; Fourche J; Bébéar C
Eur J Clin Microbiol; 1987 Oct; 6(5):584-6. PubMed ID: 3125050
[TBL] [Abstract][Full Text] [Related]
30. In vitro bactericidal activity of oxazolidinone, RBx 8700 against Mycobacterium tuberculosis and Mycobacterium avium complex.
Rao M; Sood R; Malhotra S; Fatma T; Upadhyay DJ; Rattan A
J Chemother; 2006 Apr; 18(2):144-50. PubMed ID: 16736882
[TBL] [Abstract][Full Text] [Related]
31. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment.
Abshire R; Cockrum P; Crider J; Schlech B
Clin Ther; 2004 Feb; 26(2):191-6. PubMed ID: 15038942
[TBL] [Abstract][Full Text] [Related]
32. In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
Shen GH; Wu BD; Wu KM; Chen JH
Antimicrob Agents Chemother; 2007 May; 51(5):1849-51. PubMed ID: 17353252
[TBL] [Abstract][Full Text] [Related]
33. [In vitro antimycobacterial activity of a new quinolone, NM394].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Aug; 68(8):517-20. PubMed ID: 8397311
[TBL] [Abstract][Full Text] [Related]
34. New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis.
Barluenga J; Aznar F; García AB; Cabal MP; Palacios JJ; Menéndez MA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5717-22. PubMed ID: 16987658
[TBL] [Abstract][Full Text] [Related]
35. [Components of monitoring drug resistance of tuberculosis agent in the evaluation of effectiveness of the national tuberculosis control program].
Popov SA; Dorozhkova IR; Medvedeva IM
Probl Tuberk; 2001; (2):18-20. PubMed ID: 11490457
[TBL] [Abstract][Full Text] [Related]
36. In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.
Vera-Cabrera L; Castro-Garza J; Rendon A; Ocampo-Candiani J; Welsh O; Choi SH; Blackwood K; Molina-Torres C
Antimicrob Agents Chemother; 2005 Oct; 49(10):4351-3. PubMed ID: 16189119
[TBL] [Abstract][Full Text] [Related]
37. New series of isoniazid hydrazones linked with electron-withdrawing substituents.
Vavříková E; Polanc S; Kočevar M; Košmrlj J; Horváti K; Bosze S; Stolaříková J; Imramovský A; Vinšová J
Eur J Med Chem; 2011 Dec; 46(12):5902-9. PubMed ID: 22018878
[TBL] [Abstract][Full Text] [Related]
38. The oriented development of antituberculotics: salicylanilides.
Waisser K; Matyk J; Divisová H; Husáková P; Kunes J; Klimesová V; Kaustová J; Möllmann U; Dahse HM; Miko M
Arch Pharm (Weinheim); 2006 Nov; 339(11):616-20. PubMed ID: 17048291
[TBL] [Abstract][Full Text] [Related]
39. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
[TBL] [Abstract][Full Text] [Related]
40. In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
Rao SS; Raghunathan R; Ekambaram R; Raghunathan M
Int J Antimicrob Agents; 2009 Nov; 34(5):451-3. PubMed ID: 19625168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
